Evidence map›Paper›PMID 35054313›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Metabolic Tumour Volume as a Predictor of Survival for Sinonasal Tract Squamous Cell Carcinoma.

Hidenori Suzuki, Tsuneo Tamaki, Takeshi Kodaira, Masami Nishio, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Michi Sawabe, Nobuhiro Hanai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hidenori SuzukiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Tsuneo TamakiDepartment of Radiology, Nagoya Radiological Diagnosis Foundation, Nagoya 464-8681, Japan.ORCID 0000-0002-2278-194X
Takeshi KodairaDepartment of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Masami NishioDepartment of Radiology, Nagoya Radiological Diagnosis Foundation, Nagoya 464-8681, Japan.
Daisuke NishikawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Shintaro BeppuDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Hoshino TeradaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Michi SawabeDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Aichi Cancer Center · JPNagoya University Hospital · JP

Funding

JSPS KAKENHI Grant Number of 21K09575
6 · The paper itself

Abstract

backgroundHigh uptake of F18-fluorodeoxyglucose parameters for glucose metabolism is related to shorter survival in sinonasal tract cancer with various histological classifications. We investigated whether F18-fluorodeoxyglucose uptake parameters are associated with survival outcomes for patients with only squamous cell carcinoma (SCC) in the sinonasal tract that are treated either with surgery or nonsurgery.

methodsWe retrospectively observed F18-fluorodeoxyglucose uptake parameters on positron emission tomography with computed tomography for the primary tumour of SCC in 39 patients. Log-rank test or a Cox regression model with 95% confidence interval (95%CI) and hazard ratio (HR) were used for monovariable or multivariable analysis, respectively. We determined cut-off values of the F18-fluorodeoxyglucose uptake parameters using the lowest

resultsMonovariable analysis showed that patients with metabolic tumour volume (MTV) ≥ 21.8 had a shorter cancer-specific, disease-free and local recurrence-free survival than those with MTV < 21.8. After adjusting for age, gender, clinical stage and treatment group in the multivariable analysis, MTV (≥21.8/<21.8) was related to shorter cancer-specific (HR: 3.69, 95%CI: 1.17-12.0), disease-free (HR: 3.38, 95%CI: 1.19-9.71) and local recurrence-free (HR: 5.42, 95%CI: 1.59-20.3) survivals.

conclusionsMTV as advances in diagnostics of sinonasal tract SCC is a predictor.

Indexed as

cancer-specific survivalmetabolic tumour volumepredictorsinonasal tractsquamous cell carcinoma

Identifiers

PMID35054313
PMCPMC8775068
OpenAlexW4205753887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.